“I can assure you that all the pharma/biotech companies are putting all manufacturing capability into the production”
I disagree and that’s an inaccurate reflection of the use of bioreactors. Perhaps toward available bioreactors, but they’re not dumping other oncology products to make room for new production nor are there federal DPAs with rated orders requiring first of line production as it.
Other broad comments, the antiviral production should scale up in the months ahead, but this was a tremendous fail by the federal government not to clear CMO space via DPA. Other products may also bare fruit like oral form remdesivir, which is itself actually an antiviral (and the FDA would be wise to expedite oral form rather than just authorize the intravaneous for outpatient).
On vaccines, people seeking a pan-coronavirus vaccine may be disappointed. Ditto variant specific boosters given anything likely to displace Omicron would be more transmissible and the flash to bang for turning it to market is at least 90 days (by contrast, omicron is only 90 days old and you don’t launch a production until you’re sure it’s actually taken hold). On the positive side, early winter’s mrna data from Moderna showing a combo covid-influenza-rsv vax would enable a better seasonal match to flu as well and hit theoretical future boosters.
“I can assure you that all the pharma/biotech companies are putting all manufacturing capability into the production”
I disagree and that’s an inaccurate reflection of the use of bioreactors. Perhaps toward available bioreactors, but they’re not dumping other oncology products to make room for new production nor are there federal DPAs with rated orders requiring first of line production as it.
Other broad comments, the antiviral production should scale up in the months ahead, but this was a tremendous fail by the federal government not to clear CMO space via DPA. Other products may also bare fruit like oral form remdesivir, which is itself actually an antiviral (and the FDA would be wise to expedite oral form rather than just authorize the intravaneous for outpatient).
On vaccines, people seeking a pan-coronavirus vaccine may be disappointed. Ditto variant specific boosters given anything likely to displace Omicron would be more transmissible and the flash to bang for turning it to market is at least 90 days (by contrast, omicron is only 90 days old and you don’t launch a production until you’re sure it’s actually taken hold). On the positive side, early winter’s mrna data from Moderna showing a combo covid-influenza-rsv vax would enable a better seasonal match to flu as well and hit theoretical future boosters.